Menu
Oslo, Norway, 26 June 2025: Reference is made to the stock exchange announcements by Thor Medical ASA (the "Company") on 18 June 2025 regarding the successful completion of a private placement of new shares (the "Private Placement") raising gross proceeds of approximately NOK 75 million and a retail offering of new shares (the "PrimaryBid Offering") raising gross proceeds of approximately NOK 11.4 million, and the disclosure of large shareholding notification on 18 June 2025 regrading, inter alia, the effectuation of a share loan under a share lending agreement entered into by and between the Company, its shareholder Scatec Innovation AS as share lender and Arctic Securities AS and DNB Carnegie, a part of DNB Bank ASA, as managers (the "Managers"), to facilitate delivery-versus-payment settlement in the Privat Placement and the PrimaryBid Offering (the "Share Lending Agreement").
Today, following registration of the share capital increases pertaining to the Private Placement and the PrimaryBid Offering, the Managers will redeliver 31,577,399 new shares in the Company to Scatec Innovation AS pursuant to the Share Lending Agreement. Following the effectuation of the redelivery of 31,577,399 new shares in the Company and the delivery of 3,000,000 new shares allocated to Scatec Innovation AS in the Private Placement, Scatec Innovation AS' holding of shares in the Company will be 81,419,309, equivalent to approx. 23.3% of the issued share capital and votes. Consequently, Scatec Innovation AS will cross above the 15% and 20% thresholds pursuant to section 4-2 (1) and (3) of the Norwegian Securities Trading Act.
In addition, Scatec Innovation AS has controlling interest in Scatec Invest IV AS, which holds 354,453 shares in the Company. Scatec Innovation AS aggregated holding of shares is thus 81,773,762, equivalent to approx. 23.4% of the shares and votes in the Company.
Scatec Innovation AS is a close associate of chairman John Andersen. Primary insider notification pursuant to the market abuse regulation article 19 is attached.
This announcement is published in accordance with section 4-2 of the Norwegian Securities Trading Act and is subject to disclosure requirements pursuant to the EU Market Abuse Regulation article 19 (3) and the Norwegian Securities Trading Act section and 5-12.
Contacts
Brede Ellingsæter, CFO & COO, Thor Medical ASA, +47 472 38 440, brede.ellingseter@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit www.thormedical.com
